

National Health and Medical Research Council

Entity resources and planned performance

National Health and Medical Research Council

Section 1: Entity overview and resources	436
1.1 Strategic direction statement.....	436
1.2 Entity resource statement.....	437
1.3 Budget measures	439
Section 2: Outcomes and planned performance	440
2.1 Budgeted expenses and performance for Outcome 1	440
Section 3: Budgeted financial statements.....	448
3.1 Budgeted financial statements	448
3.2 Budgeted financial statements tables.....	449

National Health and Medical Research Council

Section 1: Entity overview and resources

1.1 Strategic direction statement¹

The National Health and Medical Research Council (NHMRC) is the Australian Government's key entity for managing investment in health and medical research. NHMRC is also responsible for developing evidence-based health advice for the Australian community, health professionals and governments, and for promoting the highest standards of ethics and integrity in health and medical research.

NHMRC continues to support high quality research through its grant program, which encourages innovation in research and provides opportunities for talented researchers at all career stages. This work is facilitated by NHMRC's modern grants management solution, Sapphire, which has streamlined the application, peer review assessment and grant management processes.

NHMRC continues to support the Department of Health, Disability and Ageing to deliver the Medical Research Future Fund (MRFF) grant opportunities. NHMRC is also working with the Department to improve alignment and coordination between the MRFF and NHMRC's grant program, delivered through the Medical Research Endowment Account (MREA), and to support the National Strategy for Health and Medical Research.

NHMRC's work also facilitates and promotes the translation of evidence from health and medical research into practices, policies and products designed to prevent and treat illness and improve the health of the Australian community. NHMRC's guidelines and advice support states and territories in achieving consistent standards in public and environmental health.

The role and functions of NHMRC are set out in the *National Health and Medical Research Council Act 1992*. NHMRC also has statutory obligations under the *Prohibition of Human Cloning for Reproduction Act 2002*, the *Research Involving Human Embryos Act 2002*, and the *Medical Research Future Fund Act 2015*. NHMRC is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

¹ For more information about the strategic direction of the NHMRC, refer to the current Corporate Plan, available at: www.nhmrc.gov.au/about-us/corporate-plans-and-annual-reports

1.2 Entity resource statement

Table 1.1 shows the total resourcing from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity’s operations) classification.

For more detailed information on special accounts and special appropriations, please refer to the *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the ‘Budgeted expenses by Outcome 1’ tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis. Amounts presented below are consistent with amounts presented in the Appropriation Bills themselves.

Table 1.1: NHMRC resource statement – Budget estimates for 2026–27 as at Budget May 2026

	2025–26 Estimated actual \$'000	2026–27 Estimate \$'000
DEPARTMENTAL		
Prior year appropriation available	12,654	12,654
Annual appropriations		
Ordinary annual services ^(a)		
Departmental appropriation	48,122	51,848
s74 retained revenue receipts ^(b)	5,974	12,847
Departmental Capital Budget ^(c)	192	195
Other services ^(d)		
Equity injection	-	-
Total departmental annual appropriations	54,288	64,890
Total departmental resourcing for NHMRC	66,942	77,544

Table 1.1: NHMRC resource statement – Budget estimates for 2026–27 as at Budget May 2026 (continued)

	2025–26 Estimated actual \$'000	2026–27 Estimate \$'000
ADMINISTERED		
Annual appropriations		
Ordinary annual services ^(a)		
Outcome 1	973,172	995,919
Other services ^(d)		
Administered assets and liabilities	-	-
Total administered annual appropriations	973,172	995,919
Special accounts ^(e)		
Opening balance	391,319	352,923
Appropriation receipts	959,396	981,869
Appropriation receipts - other entities ^(f)	10,000	10,000
Non-appropriation receipts	-	-
Total special accounts	1,360,715	1,344,792
Total administered resourcing	2,333,887	2,340,711
Less appropriations drawn from annual or special appropriations above and credited to special accounts ^(g)	(959,396)	(981,869)
Total administered resourcing	1,374,491	1,358,842
Total resourcing for NHMRC	1,441,433	1,436,386
	2025–26	2026–27
Average staffing level (number)	205	205

All figures are GST exclusive.

^(a) Appropriation Bill (No. 1) 2026–2027.

^(b) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

^(c) Departmental Capital Budgets are not separately identified in Appropriation Bill (No.1) and form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

^(d) Appropriation Bill (No. 2) 2026–2027.

^(e) For further information on special appropriations and special accounts, please refer to Budget Paper No. 4 - Agency Resourcing. Also see Table 2.1 within this chapter for further information on outcome and program expenses broken down by various funding sources, e.g. annual appropriations, special appropriations and special accounts.

^(f) Appropriation receipts from the Department of Health, Disability and Ageing.

^(g) Appropriation receipts included above.

1.3 Budget measures

Budget measures in Part 1 relating to the NHMRC are detailed in the Budget Paper No. 2 and are summarised below.

Table 1.2: NHMRC 2026–27 Budget measures

Part 1: Measures announced since the 2025–26 Mid-Year Economic and Fiscal Outlook (MYEFO)

		2025–26	2026–27	2027–28	2028–29	2029–30
	Program	\$'000	\$'000	\$'000	\$'000	\$'000
Boosting Productivity – Promoting Research, Development and Innovation^(a)						
National Health and Medical Research Council						
	Departmental payments	1.1	-	12,962	11,292	-
	Total payments		-	12,962	11,292	-
Reducing Spending on Consultants, Contractors and Labour Hire, and Non-wages Expenses - one year extension^(a)						
National Health and Medical Research Council						
	Departmental payments	1.1	-	-	-	(916)
	Total payments		-	-	-	(916)

Prepared on a Government Financial Statistics (Underlying Cash) basis. Figures displayed as a negative (-) represent a decrease in funds and a positive (+) represent an increase in funds.

^(a) NHMRC is not the lead entity for this measure. NHMRC impacts only are shown in this table.

Section 2: Outcomes and planned performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs which contribute to government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

Note:

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth performance framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measure described in Portfolio Budget Statements will be read with broader information provided in an entity's corporate plans and annual performance statements – included in Annual Reports – to provide a complete picture of an entity's planned and actual performance.

The most recent Corporate Plan and Annual Performance Statements for the NHMRC can be found at: www.nhmrc.gov.au/about-us/corporate-plans-and-annual-reports

2.1 Budgeted expenses and performance for Outcome 1

Outcome 1

Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health.

Program contributing to Outcome 1

Program 1.1: Health and Medical Research

Linked Programs

Other Commonwealth entities that contribute to Outcome 1
Australian Centre for Disease Control (Australian CDC)
<p>Program 1.1: Analyse, understand and advise to support health protection planning and preparedness</p> <p>The Australian CDC contributes to NHMRC’s work by identifying public health threats and evidence gaps and providing response insights that help shape priorities for research, guidelines and health advice.</p>
Department of Health, Disability and Ageing
<p>Program 1.1: Health Research, Coordination and Access</p> <p>Program 1.8: Health Protection, Emergency Response and Regulation</p> <p>The Department of Health, Disability and Ageing contributes to health and medical research through the Medical Research Future Fund, which will support the sustainability of the health system into the future, and drive further medical innovation (1.1).</p> <p>The Department of Health, Disability and Ageing contributes to the promotion of public health and related areas that contribute to the protection and regulation of health (1.8).</p>

Budgeted expenses for Outcome 1

This table shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by Administered and Departmental funding sources.

Table 2.1.1: Budgeted expenses for Outcome 1

Outcome 1: Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health.

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
Program 1.1: Health and Medical Research					
Administered expenses					
Ordinary annual services ^(a)	973,172	995,919	1,017,828	1,039,200	1,063,101
to Medical Research Endowment Account	(959,396)	(981,869)	(1,003,458)	(1,024,858)	(1,048,429)
Special accounts					
Medical Research Endowment Account	1,007,792	1,058,792	1,094,609	1,123,402	1,146,255
Departmental expenses					
Departmental appropriation ^(b)	51,380	61,854	60,052	48,673	48,581
Expenses not requiring appropriation in the Budget year ^(c)	5,803	5,622	5,450	5,693	5,927
Operating deficit (surplus)	(2,987)	(2,681)	(2,382)	(2,751)	(3,016)
Total for Program 1.1	1,075,764	1,137,637	1,172,099	1,189,359	1,212,419
Total expenses for Outcome 1	1,075,764	1,137,637	1,172,099	1,189,359	1,212,419

	2025–26	2026–27
Average staffing level (number)	205	205

^(a) Appropriation Bill (No. 1) 2026–2027.

^(b) Departmental appropriation combines 'Ordinary annual services Appropriation Bill (No. 1)' and 'Revenue from independent sources (s74)'.

^(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expense and audit fees.

Performance measures for Outcome 1

Table 2.1.2 details the performance measures for each program associated with Outcome 1. It is used by entities to describe the results they plan to achieve and the related key activities, as detailed in the current corporate plan, the context in which these activities are delivered, and how the performance of these activities will be measured. Where relevant, details of the 2026–27 Budget measures that have created new programs or materially changed existing programs are provided.

Table 2.1.2: Performance measures for Outcome 1

<p>Outcome 1 Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health.</p>	
<p>Program 1.1: Health and Medical Research The Australian Government, through NHMRC, aims to:</p> <ul style="list-style-type: none"> • create knowledge and build research capability through investment in the highest quality health and medical research, and the best researchers (Investment) • drive the translation of health and medical research into public policy, health systems and clinical practice, and support the commercialisation of research discoveries (Translation) • maintain a strong integrity framework underpinning rigorous and ethical research, and promoting community trust (Integrity). 	
<p>Key Activities</p>	<ul style="list-style-type: none"> • Deliver funding schemes that invest in the best researchers and research to meet Australia's diverse health and medical research needs and invest in innovative and collaborative research projects (Investment) • Develop and update guidelines in public, clinical and environmental health to support consistent standards, promote prevention and public health and inform clinical, policy and regulatory decision (Translation) • Promote best-practice evidence review and standards, including support for rapidly updated and living guidelines, Guidelines for Guidelines and approval of third-party public health and clinical practice guidelines (Translation) • Maintain national standards, codes and guidelines that promote best practice in research governance and ethics review processes and provide guidance on ethical issues in health (Integrity) • Promote research integrity, including maintaining the Australian Code for the Responsible Conduct of Research and other guidance, and supporting the work of the Australian Research Integrity Committee (Integrity).

Program 1.1: Health and Medical Research		
Year	Performance Measure	Expected Performance Results
Current Year 2025–26	Research grants in basic science, clinical medicine, public health and health services research meet the health needs of Australians, and include national, state and territory and community priorities.	<p>Target 1: Grants are awarded based on expert peer review, across the full spectrum of health and medical research areas.</p> <p>Expected Performance Result: Grants were awarded based on expert peer review, across the full spectrum of health and medical research areas.²</p> <p>Target: On track</p> <p>Target 2: More than 5% of NHMRC’s annual budget is awarded to research that aims to provide better health outcomes for Aboriginal and Torres Strait Islander people.</p> <p>Expected Performance Result: More than 5% of NHMRC’s annual research grant budget was awarded to research that aims to improve health outcomes for Aboriginal and Torres Strait Islander people.³</p> <p>Target: On track</p>
Year	Performance Measure	Planned Performance Results
Budget Year 2026–27	Research grants in basic science, clinical medicine, public health and health services research meet the health needs of Australians, and include national, state and territory and community priorities.	Grants are awarded based on expert peer review across the full spectrum of health and medical research areas. More than 5% of NHMRC’s annual research grant budget is awarded to research that aims to improve health outcomes for Aboriginal and Torres Strait Islander people.
Forward Estimates 2027–30	As per 2026–27	As per 2026–27

² This performance target has been revised for clarity since the 2025–26 Portfolio Budget Statements.

³ This performance target has been revised for clarity since the 2025–26 Portfolio Budget Statements.

Program 1.1: Health and Medical Research		
Year	Performance Measure	Expected Performance Results
Current Year 2025–26	Support an Australian health system that is research-led, evidence-based, efficient and sustainable.	<p>Target: Develop and/or approve public and environmental health and clinical practice guidelines.</p> <p>Expected Performance Results: NHMRC has developed and/or is developing the following public and environmental health and clinical practice guidelines:</p> <ul style="list-style-type: none"> • Review of 2013 Australian Dietary Guidelines (in progress) • Nutrient Reference Values (NRVs) for Australia and New Zealand – priority rolling review 2006 NRVs (Sodium, Iodine, Selenium and Vitamin B6 in progress) • Review of 2022 NHMRC Statement on e-cigarettes (in progress) • Australian Drinking Water Guidelines: review of ammonia, antimony, chlorate, cyanide, nickel and trihalomethanes fact sheets (in progress) • Australian Recreational Water Quality Guidelines (in progress) • Clinical Practice Guidelines for the care of trans and gender diverse people under the age of 18 (in progress) • Clinical Practice Guidelines for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Long COVID and Related Conditions (in progress) • Review of Guidelines for Guidelines (in progress, rolling review). <p>NHMRC has approved, or expects to approve, the following clinical practice guidelines by third parties:</p> <ul style="list-style-type: none"> • Australian Postnatal Care Guidelines • Updates to the Australian Pregnancy Care Guidelines • Clinical Practice Guidelines for the Management of Overweight and Obesity for Adults, Adolescents and Children in Australia • Updates to An Australian Living Guideline for the Pharmaceutical Management of Inflammatory Arthritis

		<ul style="list-style-type: none"> • Updates to An Australian Living Guideline for the Management of Juvenile Idiopathic Arthritis • Updates to Australian and New Zealand Living Clinical Guidelines for Stroke Management • Guideline for Use of Methylendioxyamphetamine (MDMA)-assisted Psychotherapy for Post-traumatic Stress Disorder • Guidelines for the Early Detection of Prostate Cancer in Australia • Updates to the Australian Immunisation Handbook COVID-19 chapter • Clinical Practice Guidelines for the Management of Psychosocial Disorders in Moderate to Severe Traumatic Brain Injury. <p>Target: On track</p>
Year	Performance Measure	Planned Performance Results
Budget Year 2026–27	Support an Australian health system that is research-led, evidence-based, efficient and sustainable.	Develop and/or approve public and environmental health and clinical practice guidelines.
Forward Estimates 2027–30	As per 2026–27	As per 2026–27

Program 1.1: Health and Medical Research		
Year	Performance Measure	Expected Performance Results
Current Year 2025–26	Research is conducted responsibly, ethically and with integrity in Australia.	<p>Target: Research integrity matters are managed appropriately by administering institutions in line with the requirements of the <i>Australian Code for the Responsible Conduct of Research</i>.</p> <p>Expected Performance Result: Research integrity matters were managed appropriately by administering institutions in line with the requirements of the <i>Australian Code for the Responsible Conduct of Research</i>.</p> <p>Target: On track</p>
Year	Performance Measure	Planned Performance Results
Budget Year 2026–27	Research is conducted responsibly, ethically and with integrity in Australia.	Research integrity matters are managed appropriately by administering institutions in line with the requirements of the <i>Australian Code for the Responsible Conduct of Research</i> .
Forward Estimates 2027–30	As per 2026–27	As per 2026–27
Material changes to Program 1.1 resulting from 2026–27 Budget Measures: Nil		

Section 3: Budgeted financial statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2026–27 Budget year, including the impact of budget measures and resourcing on financial statements.

3.1 Budgeted financial statements

3.1.1 Differences between entity resourcing and financial statements

The NHMRC provides assistance for the medical research through the Medical Research Endowment Account (MREA) special account established under the *National Health and Medical research Council Act 1992* (NHMRC Act). The purpose of the MREA is outlined in section 51 of the NHMRC Act.

Table 3.1.1: Estimates of Special Account Cash Flows and Balances

		Opening balance 2026–27 2025–26	Other receipts 2026–27 2025–26	Appropriation receipts 2026–27 2025–26	Payments 2026–27 2025–26	Closing balance 2026–27 2025–26
	Outcome	\$'000	\$'000	\$'000	\$'000	\$'000
Medical Research Endowment Account	1	352,923 391,319	10,000 10,000	981,869 959,396	1,058,792 1,007,792	286,000 352,923
Total Special Accounts						
2026–27 estimate		352,923	10,000	981,869	1,058,792	286,000
<i>2025–26 estimated actual</i>		<i>391,319</i>	<i>10,000</i>	<i>959,396</i>	<i>1,007,792</i>	<i>352,923</i>

3.1.2 Explanatory notes and analysis of budgeted financial statements

Departmental Resources

Comprehensive Income Statement (showing net cost of services)

Revenue and expenditure for 2026–27 is expected to be in line with Government forecasts, with employee expenses to be 58% of total expenditure.

Balance Sheet

Assets and Liabilities are expected to remain stable across the Budget and forward years.

Administered Resources

The Administered accounts are used as a mechanism to transfer the majority of funds to NHMRC’s Special Account (Medical Research Endowment Account). In 2026–27 the transfer to the Special Account is expected to be \$982 million.

3.2 Budgeted financial statements tables

Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
EXPENSES					
Employee benefits	38,244	39,149	39,743	39,743	39,743
Supplier expenses	12,918	22,528	20,175	8,505	8,290
Depreciation and amortisation	5,903	5,722	5,550	5,793	6,027
Interest on RoU	118	77	34	325	448
Total expenses	57,183	67,476	65,502	54,366	54,508
LESS:					
OWN-SOURCE INCOME					
Revenue					
Sale of goods and rendering of services	12,847	12,847	12,847	12,847	11,834
Total revenue	12,847	12,847	12,847	12,847	11,834
Gains					
Other	100	100	100	100	100
Total gains	100	100	100	100	100
Total own-source income	12,947	12,947	12,947	12,947	11,934
Net cost of (contribution by) services	44,236	54,529	52,555	41,419	42,574
Revenue from Government	41,249	51,848	50,173	38,668	39,558
Surplus (deficit)	(2,987)	(2,681)	(2,382)	(2,751)	(3,016)
Surplus (deficit) attributable to the Australian Government	(2,987)	(2,681)	(2,382)	(2,751)	(3,016)
OTHER COMPREHENSIVE INCOME					
Changes in asset revaluation reserves	-	-	-	-	-
Total other comprehensive income (loss)	-	-	-	-	-
Total comprehensive income (loss) attributable to the Australian Government	(2,987)	(2,681)	(2,382)	(2,751)	(3,016)

Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June (continued)

Note: Impact of net cash appropriation arrangements

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
Total comprehensive income (loss) attributable to the Australian Government	(2,987)	(2,681)	(2,382)	(2,751)	(3,016)
plus: non-appropriated expenses depreciation/amortisation expenses	3,172	3,011	2,839	2,711	2,705
plus: depreciation/amortisation expenses for RoU assets	2,731	2,711	2,711	3,082	3,322
less: lease principal repayments	(2,916)	(3,041)	(3,168)	(3,042)	(3,011)
Total comprehensive income (loss) attributable to the agency	-	-	-	-	-

Prepared on Australian Accounting Standards basis.

RoU = Right-of-Use asset

Table 3.2: Budgeted departmental balance sheet (as at 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
ASSETS					
Financial assets					
Cash and cash equivalents	-	-	-	-	-
Receivables	13,207	13,207	13,207	13,207	13,207
Total financial assets	13,207	13,207	13,207	13,207	13,207
Non-financial assets					
Property, plant and equipment	1,291	1,010	813	863	923
Land and buildings	6,434	3,723	1,012	13,905	10,583
Intangibles	16,638	14,103	11,657	9,097	6,537
Other	1,210	1,210	1,210	1,210	1,210
Total non-financial assets	25,573	20,046	14,692	25,075	19,253
Total assets	38,780	33,253	27,899	38,282	32,460
LIABILITIES					
Payables					
Suppliers	1,216	1,216	1,216	1,216	1,216
Other payables	5,197	5,197	5,197	5,197	5,197
Total payables	6,413	6,413	6,413	6,413	6,413
Interest bearing liabilities					
Leases	7,439	4,398	1,230	14,163	11,152
Total interest bearing liabilities	7,439	4,398	1,230	14,163	11,152
Provisions					
Employees	8,662	8,662	8,662	8,662	8,662
Total provisions	8,662	8,662	8,662	8,662	8,662
Total liabilities	22,514	19,473	16,305	29,238	26,227
Net Assets	16,266	13,780	11,594	9,044	6,233
EQUITY					
Contributed equity	17,768	17,963	18,159	18,360	18,565
Reserves	1,367	1,367	1,367	1,367	1,367
Retained surpluses or (accumulated deficits)	(2,869)	(5,550)	(7,932)	(10,683)	(13,699)
Total equity	16,266	13,780	11,594	9,044	6,233

Prepared on Australian Accounting Standards basis.

Table 3.3: Departmental statement of changes in equity – summary of movement (Budget year 2026–27)

	Retained earnings	Asset revaluation reserve	Contributed equity/ capital	Total equity
	\$'000	\$'000	\$'000	\$'000
Opening balance as at 1 July 2026				
Balance carried forward from previous period	(2,869)	1,367	17,768	16,266
Surplus (deficit) for the period	(2,681)	-	-	(2,681)
Capital budget - Bill 1 (DCB)	-	-	195	195
Estimated closing balance as at 30 June 2027	(5,550)	1,367	17,963	13,780

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

Table 3.4: Budgeted departmental statement of cash flows (for the period ended 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Goods and services	12,847	12,847	12,847	12,847	11,834
Appropriations	41,249	51,848	50,173	38,668	39,558
Net GST received	-	-	-	-	-
Total cash received	54,096	64,695	63,020	51,515	51,392
Cash used					
Employees	38,244	39,149	39,743	39,743	39,743
Suppliers	12,818	22,428	20,075	8,405	8,190
Interest payments on lease liability	118	77	34	325	448
Total cash used	51,180	61,654	59,852	48,473	48,381
Net cash from (or used by) operating activities	2,916	3,041	3,168	3,042	3,011
INVESTING ACTIVITIES					
Cash used					
Purchase of property, plant and equipment	192	195	196	201	205
Total cash used	192	195	196	201	205
Net cash from (or used by) investing activities	(192)	(195)	(196)	(201)	(205)
FINANCING ACTIVITIES					
Cash received					
Equity injections - Bill 2	-	-	-	-	-
Capital budget - Bill 1 (DCB)	192	195	196	201	205
Total cash received	192	195	196	201	205
Cash used					
Lease principal repayments	2,916	3,041	3,168	3,042	3,011
Total cash used	2,916	3,041	3,168	3,042	3,011
Net cash from (or used by) financing activities	(2,724)	(2,846)	(2,972)	(2,841)	(2,806)
Net increase (or decrease) in cash held	-	-	-	-	-
Cash and cash equivalents at the beginning of the reporting period	-	-	-	-	-
Cash and cash equivalents at the end of the reporting period	-	-	-	-	-

Prepared on Australian Accounting Standards basis.

OPA = Official Public Account
DCB = Departmental Capital Budget

Table 3.5: Departmental capital budget statement (for the period ended 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
CAPITAL APPROPRIATIONS					
Capital budget - Bill 1 (DCB)	192	195	196	201	205
Equity injections - Bill 2	-	-	-	-	-
Total capital appropriations	192	195	196	201	205
Total new capital appropriations represented by:					
Purchase of non-financial assets	192	195	196	201	205
Total items	192	195	196	201	205
PURCHASE OF NON-FINANCIAL ASSETS					
Funded by capital appropriations - equity injection ^(a)	-	-	-	-	-
Funded by capital appropriation - DCB ^(b)	192	195	196	201	205
Funded internally from departmental resources	-	-	-	-	-
Total acquisitions of non-financial assets	192	195	196	201	205
RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE					
Total purchases	192	195	196	201	205
Total cash used to acquire assets	192	195	196	201	205

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

^(a) Includes current Appropriation Bill (No. 2) and prior *Appropriation Act (No. 2/4/6)* appropriations.

^(b) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.6: Statement of departmental asset movements (Budget year 2026–27)

	Buildings	Property, plant and equipment	Intangibles	Total
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2026				
Gross book value	-	4,309	34,154	38,463
Gross book value - RoU	23,831	-	-	23,831
Accumulated depreciation/ amortisation and impairment	-	(3,018)	(17,516)	(20,534)
Accumulated depreciation/amortisation and impairment - RoU	(17,397)	-	-	(17,397)
Opening net book balance	6,434	1,291	16,638	24,363
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or replacement assets				
By purchase - appropriation ordinary annual services	-	195	-	195
By purchase - RoU	-	-	-	-
Total additions	-	195	-	195
Other movements				
Depreciation/amortisation expense	-	(476)	(2,535)	(3,011)
Depreciation/amortisation expense - RoU	(2,711)	-	-	(2,711)
Other movements	-	-	-	-
Total other movements	(2,711)	(476)	(2,535)	(5,722)
As at 30 June 2027				
Gross book value	-	4,504	34,154	38,658
Gross book value - RoU	23,831	-	-	23,831
Accumulated depreciation/amortisation and impairment	-	(3,494)	(20,051)	(23,545)
Accumulated depreciation/amortisation and impairment - RoU	(20,108)	-	-	(20,108)
Closing net book balance	3,723	1,010	14,103	18,836

Prepared on Australian Accounting Standards basis.

RoU = Right-of-Use Asset

Table 3.7: Schedule of budgeted income and expenses administered on behalf of Government (for the period ended 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT					
Grants - MREA	1,007,792	1,058,792	1,094,609	1,123,402	1,146,255
Suppliers	13,776	14,050	14,370	14,342	14,661
Total expenses administered on behalf of Government	1,021,568	1,072,842	1,108,979	1,137,744	1,160,916
REVENUES ADMINISTERED ON BEHALF OF GOVERNMENT					
Recoveries	5,000	5,000	5,000	5,000	5,000
Sales of goods and services	5,000	5,000	5,000	5,000	5,000
Total income administered on behalf of Government	10,000	10,000	10,000	10,000	10,000

Prepared on Australian Accounting Standards basis.

MREA = Medical Research Endowment Account

Table 3.8: Schedule of budgeted assets and liabilities administered on behalf of Government (as at 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT					
Financial assets					
Cash and cash equivalents	353,017	286,094	204,943	116,399	28,584
Receivables	262	262	262	262	262
Total financial assets	353,279	286,356	205,205	116,661	28,846
Non-Financial assets					
Other non-financial assets	762	762	762	762	762
Total non-financial assets	762	762	762	762	762
Total assets administered on behalf of Government	354,041	287,118	205,967	117,423	29,608
LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT					
Payables					
Grants	7,747	7,747	7,747	7,747	7,747
Suppliers	-	-	-	-	-
Other	-	-	-	-	-
Total payables	7,747	7,747	7,747	7,747	7,747
Total liabilities administered on behalf of Government	7,747	7,747	7,747	7,747	7,747

Prepared on Australian Accounting Standards basis.

Table 3.9: Schedule of budgeted administered cash flows (for the period ended 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Cash received - other	10,000	10,000	10,000	10,000	10,000
Net GST received	26,000	26,000	26,000	26,000	26,000
Total cash received	36,000	36,000	36,000	36,000	36,000
Cash used					
Grant payments	1,007,792	1,058,792	1,094,609	1,123,402	1,146,255
Suppliers	13,776	14,050	14,370	14,342	14,661
Net GST paid	26,000	26,000	26,000	26,000	26,000
Total cash used	1,047,568	1,098,842	1,134,979	1,163,744	1,186,916
Net cash from (or used by) operating activities	(1,011,568)	(1,062,842)	(1,098,979)	(1,127,744)	(1,150,916)
Net increase (or decrease) in cash held	(1,011,568)	(1,062,842)	(1,098,979)	(1,127,744)	(1,150,916)
Cash at beginning of reporting period	391,413	353,017	286,094	204,943	116,399
Cash from the OPA for:					
- appropriations	973,172	995,919	1,017,828	1,039,200	1,063,101
Cash at end of reporting period	353,017	286,094	204,943	116,399	28,584

Prepared on Australian Accounting Standards basis.

OPA = Official Public Account